

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 016364-6

10/585,623

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Fenglin CHEN

FILING DATE

GROUP

July 11, 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA	5,468,619	11/1995	Senyei et al.	
	AB	5,281,522	01/1994	Senyei et al.	
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL	02/42769	05/2002	WO		X
	AM	83/00877	03/1983	WO		
	AN	28 36 362	03/1980	DE		X
	AO	9-218202	08/1997	JP		X
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

	AQ	English Abstract: American Chemical Society. Ogasawara, M. et al. "Clinical Significance of β 2 Glycoprotein I Dependent Ancicardiolipin Antibody, Lupus Anticoagulant and Antinuclear Antibodies in Patients with Recurrent Miscarriages" <i>Reproductive Immunology</i> (1998) Vol. 10, pp 272-276
	AR	English Abstract: American Chemical Society. Kano, T. et al. "The Incidence of Endometriosis and Adenomyosis in Patients with Habitual Abortion in Relation to Immunological Abnormalities" <i>Nippon Funin Gakkai Zasshi</i> (1997) Vol. 42, No. 2, pp113-118
	AS	Zhang, S. "Methods for Detecting Antinuclear Antibodies and Clinical Significance thereof" <i>Journal of Nephrophathy, Dialysis and Kidney Trnasplantation</i> (1995) Vol. 4, Issue 5, pp 495-497

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.